Although preliminary evidence indicates activity of MET inhibitors in patients with NSCLC and MET amplification, the number of evaluated patients in these trials is small, duration of the follow-up is short, and the amplification thresholds are not clearly defined and vary between the trials. The gene discussed is MET; the disease is non-small cell lung carcinoma.